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ASSOCIATION BETWEEN SERUM CONCENTRATIONS OF SOLUBLE LECTIN-
LIKE OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR-1 AND SERUM 
AMYLOID A IN TYPE 2 DIABETES 
C.H. Lee, S. Shiu, Y. Wong, K. Tan 
 
Medicine, University of Hong Kong, Hong Kong, Hong Kong 
 
BACKGROUND: Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) 
mediates the uptake of oxidized LDL in endothelial cells and macrophages, and has been 
implicated in the pathogenesis of vascular inflammation and atherosclerosis. The 
extracellular domain of LOX-1 can be proteolytically cleaved and released as a soluble 
form (sLOX-1). It has been suggested that circulating level of sLOX-1 reflects LOX-1 
expression and can act as a biomarker. LOX-1 expression is inducible and recent 
experimental data have shown that serum amyloid A (SAA), an acute phase protein, can 
induce LOX-1 expression in macrophages in vitro. Since type 2 diabetes is associated 
with subclinical inflammation, we have evaluated whether serum sLOX-1 level is 
increased in patients with type 2 diabetes and its relationship to SAA. METHOD: 300 
patients with type 2 diabetes and 150 agematched non-diabetic controls were recruited. 
Subjects with a history of any recent acute illness were excluded. Serum sLOX-1 and 
SAA were measured by ELISA. RESULT: Type 2 diabetic patients had higher serum 
sLOX-1 than controls [median 114.7 ng/ml (interquartile range 89.0–132.2) vs 102.6 
(83.8–120.3) respectively, p < 0.01] and the differences remained significant after 
adjusting for gender, body mass index and smoking. SAA was significantly increased in 
diabetic subjects than controls [129.7 ng/ml (85.8–179.3) vs 119.3 (81.6–147.9) 
respectively, p < 0.05] even in the absence of any acute illness. Serum log(sLOX-1) 
correlated significantly with log(SAA) (r = 0.51, p < 0.001) and weakly with log(eGFR) 
(r = −0.11, p = 0.05) in diabetic patients but not in non-diabetic controls. On linear 
regression analysis, log(SAA) remained an independent determinant of sLOX-1 even 
after adjusting for age, gender, body mass index, HbA1c, eGFR and smoking in subjects 
with diabetes. CONCLUSION: Elevated sLOX-1 concentration in type 2 diabetes 
suggests that LOX-1 is upregulated and we have found a significant relationship between 
circulating sLOX-1 and SAA levels. Our results suggest that SAA may potentially play a 
role in inducing LOX-1 expression in diabetes and contribute to the development of 
atherosclerosis. 
